Commitments (Details) - USD ($) $ in Thousands |
1 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|
Feb. 11, 2020 |
Sep. 06, 2017 |
Oct. 19, 2018 |
Dec. 31, 2019 |
Dec. 31, 2018 |
Dec. 31, 2017 |
|
| Commitments (Textual) | ||||||
| Description on royalty | Under the Innovation Law the rate of royalties varies between 3% to 5% computed based on the revenues from the products that their development was also funded by grants from the IIA. Such commitment is up to the amount of grants received (dollar linked), plus interest at annual rate based on LIBOR. | |||||
| Grants total | $ 38 | |||||
| Royalty expense | 43 | $ 1,263 | $ 34 | |||
| Operating lease agreements description | The License Agreement provides for the payment of an upfront cash payment of $5,000 to CollPlant, which was paid to CollPlant in November 2018 following effectiveness of the Agreement. In addition, the License Agreement provides for a one-time non-refundable option payments of $3,000 per Option Product ($9,000 in the aggregate), and up to $30,000 of milestone payments payable as follows: (i) $5,000 upon completion of the U.S. facility design, (ii) $5,000 upon completion of production of a specified amount of BioInk, and (iii) $5,000 for FDA marketing approval for each Covered Product (up to $20,000 in the aggregate). | |||||
| VAT payables | 145 | $ 145 | ||||
| Maximum total royalty amount | $ 8,600 | |||||
| Israel [Member] | ||||||
| Commitments (Textual) | ||||||
| VAT payables | $ 521 | |||||
| Israel [Member] | Subsequent Event [Member] | ||||||
| Commitments (Textual) | ||||||
| Tax pay | $ 116 | |||||
| Tax Contingent Liability [Member] | Israel [Member] | ||||||
| Commitments (Textual) | ||||||
| Tax pay | $ 434 | |||||